Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27190515 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2RORCHDAC2CYP11B2 | |
| SCHEMBL23717650 | 0.91 | USP2 (0.42) | USP2SMN1; SMN2RORCHDAC2CYP11B2 | |
| SCHEMBL3250470 | 0.90 | USP2 (0.49) | USP2SMN1; SMN2HDAC2HDAC1HPGD | |
| SCHEMBL31716895 | 0.87 | USP2 (0.43) | USP2SMN1; SMN2RORCHPGDEPHX2 | |
| SCHEMBL21811041 | 0.81 | USP2 (0.45) | USP2SMN1; SMN2RORCHDAC2CYP11B2 | |
| SCHEMBL25952120 | 0.79 | USP2 (0.44) | USP2SMN1; SMN2RORCHDAC2CYP11B2 | |
| SCHEMBL4224125 | 0.79 | USP2 (0.44) | USP2SMN1; SMN2RORCHDAC2CYP11B2 | |
| SCHEMBL26112682 | 0.79 | USP2 (0.41) | USP2SMN1; SMN2RORCHDAC2CYP11B2 | |
| SCHEMBL358661 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2HDAC2CYP11B2USP30 | |
| SCHEMBL16590451 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2RORCHDAC2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHROEDINGER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715642-A | Heterocyclic compounds and methods of use | 薛定谔公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022251497-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | USP2 2952/4885SMN1; SMN2 3902/4885RORC 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.